Replies to post #83331 on Biotech Values

[deut8-18]

I have heard David Bupp, Neoprobe CEO, make that projection many times. That number is also confirmed in a Dutton report, and I know you don't like paid for reports but they get their info from somewhere and yes Dutton is out-of-business but I still believe the report to be factual, that can be found on the Neoprobe Advanced Blog: http://advancedduediligence.blogspot.com/
Rigs projection from the blog:
For prognostic applications, third party consultants have estimated that the RIGS drug could command $6,000 per operative dose. With 149,000 cases of colon cancer in the U.S. (American Cancer Society) and 940,000 cases worldwide (World Health Organization) the potential annual sales for RIGS ranges from $1 Billion to $6 Billion per year, depending on market penetration. Consultants have pegged the latest estimates at $2.4 Billion.
You can listen to the webcast Thurs and see what he says: http://finance.yahoo.com/news/Neoprobe-to-Present-at-Rodman-bw-3840182883.html?x=0&.v=2

Good luck,

Deut 8:18